Evidence map›Paper›PMID 28527094›Full record

ArticleTargeted oncology2017

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Fanny Garlan, Benoit Blanchet, Nora Kramkimel, Alicja Puszkiel, Jean-Louis Golmard, Gaelle Noe, Nicolas Dupin, Pierre Laurent-Puig, Michel Vidal, Valerie Taly and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Analytic and clinical validity of thyroid nodule mutational profiling using droplet digital polymerase chain reaction.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2018
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Fanny GarlanINSERM UMR-S1147, CNRS SNC5014, Equipe Labélisée Ligue Contre le Cancer, Université Paris Descartes, Centre Université Paris Sorbonne Cité, Universitaire des Saints-Pères, Paris, France.
Benoit BlanchetAssistance Publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France.
Nora KramkimelAssistance Publique des Hôpitaux de Paris, Département de Dermatologie, Hôpital Cochin, Paris, France.
Alicja PuszkielAssistance Publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France.
Jean-Louis GolmardAssistance Publique des Hôpitaux de Paris, Département de Biostatistiques, Hôpital Pitié- Salpétrière, Paris, France.
Gaelle NoeAssistance Publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France.
Nicolas DupinAssistance Publique des Hôpitaux de Paris, Département de Dermatologie, Hôpital Cochin, Paris, France.
Pierre Laurent-PuigINSERM UMR-S1147, CNRS SNC5014, Equipe Labélisée Ligue Contre le Cancer, Université Paris Descartes, Centre Université Paris Sorbonne Cité, Universitaire des Saints-Pères, Paris, France.
Michel VidalAssistance Publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France.
Valerie TalyINSERM UMR-S1147, CNRS SNC5014, Equipe Labélisée Ligue Contre le Cancer, Université Paris Descartes, Centre Université Paris Sorbonne Cité, Universitaire des Saints-Pères, Paris, France.
Audrey Thomas-SchoemannAssistance Publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France. schoemann.audrey@gmail.com.
Hôpital Cochin · FRDélégation Paris 5 · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating tumor DNA (ctDNA) has been reported as a prognostic marker in melanoma. In BRAF V600-mutant melanoma, a plasma under-exposure to vemurafenib could favor emerging resistance but no biological data are available to support this hypothesis.

objectiveWe aimed to investigate the relationship between vemurafenib plasma concentrations and the ctDNA plasma concentration during follow-up of BRAF-mutated melanoma patients. PATIENTS AND

methodsEleven patients treated with single-agent vemurafenib for advanced BRAF V600-mutant melanoma were analyzed in an exploratory monocentric study. The vemurafenib plasma concentration was measured by liquid chromatography. ctDNA was extracted from plasma samples and the ctDNA concentration was evaluated using picoliter droplet-based digital PCR with Taqman

resultsAt baseline, plasma ctDNA was detectable in 72% (n = 8/11) of patients and the ctDNA concentration decreased in 88% of these patients (n = 7/8) from day (D) 0 to D15 after vemurafenib initiation. During follow-up, an increased ctDNA concentration was detected in nine patients: in five patients, the first increase in ctDNA concentrations followed a decrease in vemurafenib concentrations. More interestingly, an inverse correlation between vemurafenib concentration and ctDNA concentrations was demonstrated (p = 0.026). The ctDNA concentration at baseline was associated with overall survival (hazard ratio = 2.61, 95% CI 1.04-6.56; p = 0.04).

conclusionsThis study demonstrates the relevance of vemurafenib plasma monitoring during the follow-up of metastatic melanoma patients. Plasma drug monitoring and ctDNA concentrations could be combined to monitor tumor evolution in melanoma patients treated with anti-BRAF therapies.

Indexed as

AdultAgedAntineoplastic AgentsDNAFemaleFollow-Up StudiesHumansIndolesMaleMelanomaMiddle AgedMutationNeoplasm MetastasisNeoplasm StagingPolymerase Chain ReactionPrognosisAntineoplastic AgentsDNAIndolesProto-Oncogene Proteins B-rafSulfonamidesVemurafenib

Identifiers

PMID28527094
OpenAlexW2616070534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.